Login to Your Account



On Brink of Phase III, Sophiris Files IPO to Advance BPH Bid

By Randy Osborne
Staff Writer

Tuesday, February 19, 2013
Aiming to start pivotal trials with its therapy for benign prostatic hyperplasia (BPH) before the end of the year, Sophiris Bio Inc. (formerly Protox Therapeutics Inc.) filed for an initial public offering (IPO) that specifies neither the number of shares nor the price range.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription